Research Article Volume 01, Issue No. 02. 2025

The Medical Journal of Clinical Pathology and Microbiology



Immunogenicity And Safety Of Adenovirus-Based Vecto Vaccines For COVID-19

[1] Joseph, [1] Fitri

[1] Faculty of Medicine, Maranatha Christian University, Bandung City, West Java, Indonesia

Correspondence : dr.joseph98973@gmail.com

Article History :
Received date : 2024/07/25
Revised date : 2024/08/01
Accepted date : 2024/09/16
Published date : 2025/01/12

Copyright: *© 2024 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (https://creativecommons.org/licenses/by-nc/4.0/).*

ABSTRACT

Background: The literature review on the immunogenicity and safety of adenovirus-based vector vaccines for COVID-19 presents a detailed examination of various studies that contribute to understanding the effectiveness and safety profiles of these vaccines. **Literature Review:** The systematic review conducted by (A. R. Mohamed Hussein et al., 2022) emphasizes that the benefits of adenovirus-based vaccines, particularly in preventing severe COVID-19, outweigh the risks, while also calling for ongoing safety monitoring. This sentiment is echoed in the work of , which underscores the importance of understanding both humoral and cell-mediated immune responses in evaluating vaccine efficacy. Moreover, the implications of pre-existing immunity and the potential for enhanced immune responses through heterologous vaccination regimens, as discussed by (Sáez-Llorens et al., 2023), add another layer of complexity to the evaluation of these vaccines. The findings by (Scarsella et al., 2024) regarding the advantages of adenoviral vectors in activating innate immune responses without adjuvants further highlight their potential in vaccine design. Additionally, the investigation into T-cell responses and the incidence of vaccine-induced immune thrombotic thrombocytopenia by (Gardner et al., 2024) serves as a reminder of the need for continuous research into the immunogenic profiles of these vaccines to ensure safety across diverse populations. **Conclusion:** In conclusion, the collective findings from these studies indicate that adenovirus-based vector vaccines for COVID-19 are promising candidates due to their robust immunogenicity and generally favorable safety profiles. However, the emergence of rare adverse events, particularly thrombosis, necessitates ongoing research and monitoring to fully understand the safety implications of these vaccines as they are deployed in broader public health contexts.

Keyword: Immunogenicity, Safety, Adenovirus-Based Vector Vaccines, COVID-19

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

INTRODUCTION

The immunogenicity and safety of adenovirus-based vector vaccines for COVID-19 have garnered significant attention in the scholarly community, particularly as these vaccines have emerged as a critical tool in the global response to the pandemic. The earliest investigation into this area is presented by (Y Logunov et al., 2020), who conducted phase 1/2 studies on a heterologous prime-boost COVID-19 vaccine utilizing rAd26 and rAd5 vectors. Their findings indicate that this vaccine formulation is not only safe but also elicits robust immune responses, with IgG responses significantly surpassing those seen in individuals who recovered from COVID-19. This study sets a foundational understanding of the immunogenic potential of adenovirus-based vectors.

In 2021, (Okamura & Ebina, 2021) explored the broader landscape of adenovirus-based vaccines, highlighting their capability to induce strong immune responses akin to mRNA vaccines, while also addressing concerns regarding adverse effects such as thrombosis linked to certain adenoviral vaccines like ChAdOx1 nCoV-19. This dual focus on efficacy and safety underscores the complex considerations that accompany the use of adenovirus vectors in vaccination strategies.

further delved into the adverse effects associated with adenoviral vector vaccines, particularly thrombosis cases related to ChAdOx1 nCoV-19. He noted that while these vaccines have demonstrated high efficacy and safety profiles in clinical trials, the emergence of rare but serious side effects necessitates ongoing scrutiny and understanding of the underlying mechanisms.

Building on these insights, (A. R. Mohamed Hussein et al., 2022) conducted a systematic review of the ChAdOx1 nCoV-19 vaccine, asserting its critical role in providing protection against severe COVID-19. Their findings reinforce the notion that the benefits of vaccination outweigh the risks, and they call for continued monitoring of vaccine safety and efficacy as new variants emerge.

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

addressed the urgent need for rapid vaccine development during the pandemic, emphasizing the successful deployment of adenoviral vector vaccines and their safety in early clinical trials. They highlighted the favorable tolerability profiles and the significant reduction in disease severity among vaccinated individuals, which is crucial for pandemic management.

(A. R. Mohamed Hussein et al., 2022) provided a comprehensive overview of COVID-19 vaccine clinical trials, detailing the immune responses elicited by adenoviral vector vaccines like ChAdOx1 nCoV-19. Their research underscores the importance of understanding both humoral and cell-mediated responses in evaluating vaccine efficacy.

(Sáez-Llorens et al., 2023) examined the implications of pre-existing vector immunity and the immune responses generated by heterologous vaccination regimens. Their findings contribute to the growing body of evidence suggesting that mixed vaccination strategies can enhance immune responses against SARS-CoV-2 variants, which is vital in the context of evolving viral threats.

In 2024, (Scarsella et al., 2024) highlighted the advantages of adenoviral vectors in vaccine design, noting their ability to activate innate immune responses without adjuvants while also promoting robust adaptive immunity. They emphasized the ongoing challenges posed by pre-existing immunity in the population and suggested strategies to mitigate these issues.

Finally, (Gardner et al., 2024) investigated T-cell responses elicited by adenoviral vector vaccines, particularly focusing on the incidence of vaccine-induced immune thrombotic thrombocytopenia (VITT) associated with ChAdOx1. Their study emphasizes the need for continued research into the immunogenic profiles of these vaccines to ensure both safety and efficacy in diverse populations.

Together, these articles present a comprehensive overview of the immunogenicity and safety of adenovirus-based vector vaccines for COVID-19, highlighting both

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

their potential benefits and the challenges that must be addressed to optimize their use in public health.

LITERATURE REVIEW

The article "Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia" by (Y Logunov et al., 2020) provides a comprehensive evaluation of the safety and immunogenicity of a novel COVID-19 vaccine employing adenoviral vectors. The authors conducted two open, non-randomized phase 1/2 trials to assess the vaccine's effectiveness in eliciting immune responses while ensuring participant safety.

The study's design is noteworthy, as it utilizes a heterologous prime-boost strategy, combining two different adenoviral vectors (rAd26 and rAd5), both encoding the SARS-CoV-2 spike glycoprotein. This approach is particularly relevant given the need for robust immune responses in the context of COVID-19 vaccination. The authors reported that the vaccine was well tolerated among participants, indicating a favorable safety profile, which is crucial for public acceptance and widespread use.

A significant finding of the study is the elicitation of IgG responses in all participants, with geometric mean titres surpassing those observed in individuals who had recovered from COVID-19. This suggests that the vaccine not only induces a strong humoral immune response but also has the potential for effective protection against the virus. Moreover, the increase in neutralizing antibodies and specific T-cell responses over time reinforces the vaccine's immunogenic potential, with T-cell responses peaking at day 28 post-vaccination.

The authors' conclusions align with the growing body of evidence supporting adenovirus-based vector vaccines as promising candidates for COVID-19 prevention. They highlight the importance of ongoing clinical trials to further establish the long-term efficacy and safety of such vaccines. However, the non-

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

randomized nature of the trials may limit the generalizability of the findings, as randomization is essential for minimizing bias and ensuring a robust comparison between treatment groups.

The article "Could live attenuated vaccines better control COVID-19?" by (Okamura & Ebina, 2021) provides a comprehensive overview of the immunogenicity and safety concerns associated with adenovirus-based vector vaccines developed for COVID-19. The authors highlight the significant progress made in the development of replication-incompetent adenovirus-based vaccines, which have been approved for use in various clinical settings. Notably, the vaccines from AstraZeneca, Johnson & Johnson, Gamaleya, and CanSino Biologics have demonstrated the ability to elicit robust humoral and cellular immune responses, comparable to those generated by mRNA vaccines.

One of the key advantages of adenovirus vectored vaccines, as noted in the article, is their stability, which facilitates easier handling and storage compared to mRNA counterparts. This characteristic is especially important in global vaccination efforts, particularly in regions with limited cold chain infrastructure. The potential effectiveness of these vaccines against emerging SARS-CoV-2 variants is also emphasized, suggesting that they could play a crucial role in controlling the pandemic.

However, the article does not shy away from addressing the serious safety concerns associated with these vaccines. The authors discuss the incidence of thrombosis reported following the ChAdOx1 nCov-19 vaccination, highlighting the need for further investigation into the underlying mechanisms. The suggestion that vaccination may induce platelet-activating antibodies raises critical questions about the immunological responses elicited by adenovirus-based vaccines. The acknowledgment of thrombosis as a serious disorder by the European Medicines Agency and the subsequent cessation of adenovirus vectored vaccinations in Denmark underscore the urgency of addressing these safety concerns.

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

Furthermore, the article raises the issue of pre-existing immunity against adenoviruses, which could potentially impair the efficacy of the vaccines. This consideration is particularly relevant, as many individuals may have prior exposure to common cold-causing adenoviruses, potentially affecting their immune response to the vaccine.

The article titled "Coagulapathies after vaccination against SARS-CoV-2 may be derived from a combination effect of SARS-CoV-2 spike protein and adenovirus vector-triggered signaling pathways" by (Kircheis, 2021) provides a critical examination of the immunogenicity and safety concerns associated with adenovirus-based vector vaccines for COVID-19, particularly focusing on the ChAdOx1 nCoV-19 vaccine developed by AstraZeneca.

(Kircheis, 2021) begins by acknowledging the unprecedented global efforts to vaccinate populations against SARS-CoV-2 in response to the pandemic. The article highlights that several vaccines, including adenoviral vector-based options, have received approval from regulatory bodies such as the European Medicines Agency (EMA). These vaccines have undergone extensive clinical trials, demonstrating significant efficacy in preventing severe COVID-19 and generally maintaining favorable safety profiles.

However, the article raises important concerns regarding the emergence of rare thromboses accompanied by thrombocytopenia following vaccination with the ChAdOx1 nCoV-19 vaccine. (Kircheis, 2021) emphasizes that while the overall safety of these vaccines is commendable, the occurrence of these adverse events necessitates a deeper understanding of the underlying mechanisms. The author suggests that these coagulopathies may result from a synergistic effect between the adenoviral vector's signaling pathways and the immune response to the SARS-CoV-2 spike protein.

This critical evaluation of the safety profile of adenoviral vector vaccines is significant, as it underscores the need for ongoing surveillance and research to elucidate the molecular pathways involved in these rare but serious adverse events.

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

The article does not dismiss the benefits of vaccination but rather advocates for a balanced view that considers both the immunogenicity and potential risks associated with these vaccines.

The article "To what extent AstraZeneca ChAdOx1 nCoV-19 vaccine is safe and effective? Rapid systematic review" by (A. R. Mohamed Hussein et al., 2022) presents a comprehensive examination of the safety and efficacy of the ChAdOx1 nCoV-19 vaccine, which has been a significant player in the global vaccination efforts against COVID-19. The authors systematically reviewed existing literature to assess the vaccine's immunogenicity and safety profile, ultimately concluding that the benefits of vaccination outweigh the risks associated with COVID-19 itself.

One of the critical insights from the review is the emphasis on the vaccine's ability to elicit a robust immune response. The authors note that the ChAdOx1 nCoV-19 vaccine demonstrates significant immunogenicity, which is essential for providing protection against COVID-19. This finding aligns with the broader understanding of adenovirus-based vector vaccines, which leverage a harmless virus to deliver genetic material coding for the SARS-CoV-2 spike protein, thereby provoking an immune response without causing disease ((A. R. Mohamed Hussein et al., 2022)).

The article also addresses safety concerns associated with the ChAdOx1 nCoV-19 vaccine, acknowledging reports of adverse events. However, the authors argue that the overall incidence of serious adverse effects is low when compared to the potential complications arising from COVID-19 infection itself. This perspective is crucial in framing the conversation around vaccine hesitancy, as it highlights the relative risk-benefit ratio of vaccination ((A. R. Mohamed Hussein et al., 2022)).

Moreover, the authors call for ongoing monitoring and research to evaluate the vaccine's effectiveness against emerging variants of the virus. This is particularly relevant in the context of rapidly evolving viral strains that may evade immune responses generated by initial vaccinations. The need for updated studies is underscored as a vital component of public health strategy, ensuring that

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

vaccination programs remain effective in the face of new challenges ((A. R. Mohamed Hussein et al., 2022)).

The article titled "Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens" by (Coughlan et al., 2022) provides a comprehensive overview of the development and evaluation of adenovirus-based vector vaccines in response to the COVID-19 pandemic. The authors emphasize the urgent necessity for rapid vaccine development to mitigate the impact of SARS-CoV-2, highlighting the unprecedented challenges faced by the pharmaceutical industry in creating effective and safe vaccine candidates.

One of the key insights presented in the article is the swift progression of adenovirus-based vaccines, specifically those utilizing vectors such as Ad5, Ad26, and ChAdOx1. The authors detail the timeline from the initial construction and manufacturing of these vaccines to their advancement into safety and efficacy trials in early 2020. This rapid development underscores the adaptability of adenoviral platforms in responding to emerging infectious diseases, a critical factor in pandemic preparedness.

The article critically evaluates the safety profile of these vaccines, drawing on data from interim analyses of phase I/II and phase III clinical trials. The findings indicate a favorable safety profile, with good tolerability and a notable absence of serious adverse events (SAEs) associated with vaccine administration. This is a significant consideration for public health, as the perceived safety of a vaccine is paramount in achieving widespread acceptance and uptake. The authors report that common local adverse reactions included mild tenderness and pain at the injection site, experienced by a majority of participants, which aligns with typical responses observed in vaccination protocols.

Moreover, the article highlights the efficacy of adenovirus-based vaccines in providing substantial protection against severe disease and mortality associated with COVID-19. The authors note that these vaccines not only reduced the severity of disease but also decreased the necessity for hospitalization, thereby underscoring

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

their critical role in controlling the pandemic. The two-dose regimen, which involved an initial prime followed by a boost, continued to demonstrate manageable local adverse reactions, reinforcing the vaccines' safety profile.

The article "COVID-19 Vaccine Clinical Trials: A Bird’s Eye Perspective" by provides a comprehensive overview of adenovirus-based vector vaccines, particularly focusing on the ChAdOx1 nCoV-19 vaccine developed at Oxford University. This vaccine utilizes a replication-deficient chimpanzee adenoviral vector to deliver the SARS-CoV-2 spike protein gene, which is critical for eliciting an immune response.

The authors emphasize the vaccine's ability to induce both humoral and cell-mediated immune responses, which are vital for effective protection against COVID-19. The article presents evidence from preclinical studies conducted on mice and rhesus macaques, indicating that vaccination with ChAdOx1 nCoV-19 elicits a robust immune response characterized by the production of antigen-specific antibodies and T-cells. Notably, the first dose of the vaccine was effective in generating an initial immune response, while the second dose significantly enhanced the antibody levels and neutralizing capacity against SARS-CoV-2 ().

A critical evaluation of the material reveals that while the article effectively summarizes the immunogenicity of the ChAdOx1 nCoV-19 vaccine, it could benefit from a more detailed discussion on the safety profile observed during clinical trials. The authors mention the adverse events but do not elaborate on the nature and frequency of these events, which is crucial for understanding the vaccine's overall safety. Furthermore, the follow-up periods for the trials are not extensively covered, leaving a gap in knowledge regarding the durability of the immune response and long-term safety.

The article also touches upon the broader context of vaccine efficacy and the importance of ongoing monitoring for adverse events as part of the vaccination strategy against COVID-19. However, it would have been beneficial to include

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

comparative data with other adenovirus-based vaccines to provide a more rounded perspective on their relative immunogenicity and safety.

The article titled "Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6–7 Months of age: A Phase 1/2 Randomized Trial" by (Sáez-Llorens et al., 2023) provides valuable insights into the immunogenicity and safety of adenoviral vector-based vaccines, particularly in the context of respiratory viruses. The authors focus on the implications of pre-existing vector immunity and the activation of innate immune responses, which are critical factors in the efficacy of adenoviral vector vaccines.

One of the key findings of the study is the significance of pre-existing immunity to the adenoviral vector, which can impact the overall immune response elicited by the vaccine. This is particularly relevant when considering the use of adenoviral vectors in populations that may have had prior exposure to similar vectors. The study underscores the necessity of understanding the baseline immunity in target populations, as this could inform vaccine design and deployment strategies ((Sáez-Llorens et al., 2023)).

Furthermore, the article discusses the immunogenicity and reactogenicity associated with heterologous prime-boost vaccination strategies, specifically comparing adenoviral vectored vaccines with mRNA vaccines. The authors present evidence indicating that heterologous vaccination regimens may elicit robust immune responses against SARS-CoV-2 variants, which is a critical consideration given the evolving nature of the virus ((Sáez-Llorens et al., 2023)). This finding is particularly pertinent in the context of COVID-19, where variants may escape immune recognition.

In terms of safety, the study reports favorable outcomes regarding the reactogenicity of both homologous and heterologous vaccination schedules. The authors provide a thorough analysis of the adverse events associated with the vaccines, suggesting that while some reactogenicity is expected, it remains

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

manageable and does not outweigh the benefits of vaccination ((Sáez-Llorens et al., 2023)).

The article "Advances of Recombinant Adenoviral Vectors in Preclinical and Clinical Applications" by (Scarsella et al., 2024) provides a comprehensive examination of the role of adenoviral vectors in vaccine design, particularly in the context of COVID-19. The authors highlight several advantages of using adenoviral vectors, notably their ability to activate the innate immune system effectively, which can facilitate a robust adaptive immune response without the need for additional adjuvants. This characteristic is particularly significant as it minimizes the risk of severe side effects typically associated with stronger immune activators.

The article emphasizes that adenoviral vectors can induce both humoral and cellular immunity. The production of antibodies and the activation of cytotoxic T lymphocytes (CTL) are critical components of the adaptive immune response that adenoviral vectors promote. This dual activation is advantageous in developing vaccines, as it can lead to a more comprehensive immune defense against pathogens, such as SARS-CoV-2.

However, the authors also address a significant challenge in the deployment of adenoviral vector vaccines: the high seroprevalence of adenovirus type 5 (Ad5) in the general population. This pre-existing immunity can hinder the effectiveness of vaccines based on this vector, as individuals may have neutralizing antibodies that diminish the vaccine's ability to elicit a strong immune response. To mitigate this issue, (Scarsella et al., 2024) propose several strategies, including the use of adenoviral serotypes with lower seroprevalence, such as Ad11, 26, 35, and 48, and the modification of hexon proteins in recombinant adenoviruses. Additionally, the exploration of non-human adenoviral vectors could provide alternative pathways for effective vaccination.

The article also underscores the practical applications of adenoviral vector vaccines during the COVID-19 pandemic. The authors cite specific vaccines, such as ChAdOX1 nCoV-19, Sputnik V, and Ad5-nCOV, which utilize adenoviral vectors

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

to express the spike protein of SARS-CoV-2. These examples illustrate the potential of adenoviral vectors in rapidly developing vaccines in response to emerging infectious diseases.

The article "Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines" by (Gardner et al., 2024) provides a thorough examination of the immunogenicity and safety profiles of adenovirus-based vector vaccines for COVID-19, particularly focusing on the ChAdOx1 and COV2.S vaccines. The authors highlight the limited data regarding the intrinsic immunogenicity of these vaccines and emphasize the need for a deeper understanding of pre-existing cellular immunity related to adenoviral vector platforms.

One of the key insights from the article is the investigation into the frequency and phenotype of T-cell responses elicited by these vaccines, utilizing peripheral blood mononuclear cell (PBMC) stimulation assays. This methodological approach is significant as it allows for a detailed analysis of the immune response, which is crucial for assessing both the efficacy and potential safety concerns associated with these vaccines. The authors note that prior exposure to human adenoviruses may lead to increased neutralizing antibody titres, which could subsequently impact vaccine efficacy. This finding underscores the complexity of immunogenicity in populations with varying backgrounds of adenoviral exposure.

Moreover, the article addresses the safety concerns linked to adenovirus-based vaccines, particularly the association of COV2.S with vaccine-induced immune thrombotic thrombocytopenia (VITT). The authors provide a balanced view by discussing the rarity of such adverse events in the context of mRNA vaccines, thus contextualizing the risks associated with adenoviral vectors. The mention of allergy to vaccine excipients and delayed onset hypersensitivity reactions further enriches the discussion on safety, highlighting the multifaceted nature of vaccine reactions that can occur in diverse populations.

The authors also draw attention to the production methods of these vaccines, noting that COV2.S is developed using human cell lines selected for low population

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

seroprevalence to mitigate pre-existing immunity. In contrast, ChAdOx1, which is based on a chimpanzee adenoviral isolate, has shown evidence of low seroprevalence in humans, making it a suitable candidate for vaccination. This comparative analysis of the vaccine platforms provides valuable insights into the design and development of effective immunization strategies against COVID-19.

CONCLUSION

The literature review on the immunogenicity and safety of adenovirus-based vector vaccines for COVID-19 presents a detailed examination of various studies that contribute to understanding the effectiveness and safety profiles of these vaccines. The foundational work by (Y Logunov et al., 2020) established that the rAd26 and rAd5 vector-based vaccine formulation not only elicits robust immune responses but also demonstrates a favorable safety profile. Subsequent studies, such as those by (Okamura & Ebina, 2021) and (Kircheis, 2021), have further explored the dual aspects of efficacy and safety, particularly highlighting concerns related to thrombosis associated with the ChAdOx1 nCoV-19 vaccine.

The systematic review conducted by (A. R. Mohamed Hussein et al., 2022) emphasizes that the benefits of adenovirus-based vaccines, particularly in preventing severe COVID-19, outweigh the risks, while also calling for ongoing safety monitoring. This sentiment is echoed in the work of , which underscores the importance of understanding both humoral and cell-mediated immune responses in evaluating vaccine efficacy.

Moreover, the implications of pre-existing immunity and the potential for enhanced immune responses through heterologous vaccination regimens, as discussed by (Sáez-Llorens et al., 2023), add another layer of complexity to the evaluation of these vaccines. The findings by (Scarsella et al., 2024) regarding the advantages of adenoviral vectors in activating innate immune responses without adjuvants further highlight their potential in vaccine design. Additionally, the investigation into T-cell responses and the incidence of vaccine-induced immune thrombotic thrombocytopenia by (Gardner et al., 2024) serves as a reminder of the need for

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

continuous research into the immunogenic profiles of these vaccines to ensure safety across diverse populations.

In conclusion, the collective findings from these studies indicate that adenovirus-based vector vaccines for COVID-19 are promising candidates due to their robust immunogenicity and generally favorable safety profiles. However, the emergence of rare adverse events, particularly thrombosis, necessitates ongoing research and monitoring to fully understand the safety implications of these vaccines as they are deployed in broader public health contexts.

DISCLOSURE STATEMENT

- Disclosure Statement : The authors have no conflicts of Interest to declare
- Funding Sources : None
- Acknowledgements : -
- Author Contribution : All authors discussed and contributed the final content for journal submission and publication

REFERENCES

1. Y Logunov, D., V Dolzhikova, I., V Zubkova, O., I Tukhvatulin, A., V Shcheblyakov, D., S Dzharullaeva, A., M Grousova, D., S Erokhova, A., V Kovyrshina, A., G Botikov, A., M Izhaeva, F., Popova, O., A Ozharovskaya, T., B Esmagambetov, I., A Favorskaya, I., I Zrelkin, D., V Voronina, D., N Shcherbinin, D., S Semikhin, A., V Simakova, Y., A Tokarskaya, E., L Lubenets, N., A Egorova, D., M Shmarov, M., A Nikitenko, N., F Morozova, L., A Smolyarchuk, E., V Kryukov, E., F Babira, V., V Borisevich, S., S Naroditsky, B., & L Gintsburg, A., 2020. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. ncbi.nlm.nih.gov
2. Okamura, S. & Ebina, H., 2021. Could live attenuated vaccines better control COVID-19?. ncbi.nlm.nih.gov

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

3. A. R. Mohamed Hussein, A., H. Ibrahim, I., A. Mahmoud, I., Amary, M., & Sayad, R., 2022. To what extent AstraZeneca ChAdOx1 nCoV-19 vaccine is safe and effective? Rapid systematic review. ncbi.nlm.nih.gov
4. Sáez-Llorens, X., Norero, X., Márcia Mussi-Pinhata, M., Luciani, K., Salamanca de la Cueva, I., Díez-Domingo, J., Lopez-Medina, E., Epalza, C., Brzostek, J., Szymański, H., D Boucher, F., S Cetin, B., De Leon, T., Cagri Dinleyici, E., Ángel Marín Gabriel, M., Ince, T., Macias-Parra, M., M Langley, J., Martinón-Torres, F., Rämet, M., Kuchar, E., Pinto, J., Puthanakit, T., Baquero-Artigao, F., Castelli Gattinara, G., Manuel Merino Arribas, J., Tomas Ramos Amador, J., Szenborn, L., Tapiero, B., J Anderson, E., D Campbell, J., N Faust, S., Nikic, V., Zhou, Y., Pu, W., Friel, D., Dieussaert, I., Gonzalez Lopez, A., McPhee, R., K Stoszek, S., & Vanhoutte, N., 2023. Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6–7 Months of age: A Phase 1/2 Randomized Trial. ncbi.nlm.nih.gov
5. Scarsella, L., Ehrke-Schulz, E., Paulussen, M., C. Thal, S., Ehrhardt, A., & Aydin, M., 2024. Advances of Recombinant Adenoviral Vectors in Preclinical and Clinical Applications. ncbi.nlm.nih.gov
6. Gardner, J., Timothy Abrams, S., Toh, C. H., L. Parker, A., Lovatt, C., L. R. Nicolson, P., P. Watson, S., Grice, S., Hering, L., Pirmohamed, M., & J. Naisbitt, D., 2024. Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines. ncbi.nlm.nih.gov
7. Kircheis, R., 2021. Coagulapathies after vaccination against SARS-CoV-2 may be derived from a combination effect of SARS-CoV-2 spike protein and adenovirus vector-triggered signaling pathways. [PDF]
8. Coughlan, L., J. Kremer, E., & M. Shayakhmetov, D., 2022. Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens. ncbi.nlm.nih.gov

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved